InfuSystem (INFU) Q3 2025 earnings summary

Executive summary

• Achieved record Q3 2025 net revenue of $36.5 million, up 3.3% year-over-year, with net income rising 25% to $2.3 million and adjusted EBITDA increasing 6% to $8.3 million, driven by Patient Services growth and margin expansion.

• Strategic focus on oncology, wound care, and automation, including the integration of Apollo Medical and new AI-driven billing systems.

• Signed a significant new oncology contract and a multi-year extension with a major national insurer, supporting future growth.

• Amended a large biomedical services contract, reducing revenue but increasing operating profit and margins.

• For the nine months ended September 30, 2025, net revenues grew 6.1% to $107.2 million, with net income of $4.6 million.

Financial highlights

• Gross profit for Q3 2025 was $20.8 million, up 9.3% year-over-year, with gross margin at 57.1% (up 3.1 pts year-over-year).

• Adjusted EBITDA was $8.3 million (22.8% margin), up 5.6% year-over-year; trailing 12-month Adjusted EBITDA $30.2 million (21.4% margin).

• Operating cash flow for the first nine months exceeded $17 million, up $4.8 million year-over-year.

• Net income for Q3 2025 was $2.3 million ($0.11 per diluted share), up from $1.8 million ($0.08 per share) in Q3 2024.

• Available liquidity stood at $54.6 million as of September 30, 2025.

Outlook and guidance

• Reaffirmed full-year 2025 guidance: net revenue growth projected at 6–8% and adjusted EBITDA margin expected to be 20% or higher.

• Device Solutions faces a headwind in 2026 due to the biomedical contract change, but Patient Services expected to drive growth.

• ERP project expenses to taper off after Q1 2026, with higher ongoing maintenance costs but lower one-time spend.

• Management expects continued operational improvements and margin expansion despite ongoing investments in business applications.

• Focus on organic growth in biomedical and wound care, while maintaining strong core business.